Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time). Keytruda is used in adults and some children with certain advanced forms of the following types of ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing ...

Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...

For example, Keytruda (pembrolizumab) is a type of biologic treatment ... Instead, you might take your biologic as an injection. Because biologics are delicate, they must be stored correctly (often in ...

In oncology drugs, Keytruda sales are likely to have been ... is likely to have hurt sales of neuromuscular blockade medicine ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...